Interleukin-35 expression protects against cigarette smoke-induced lung inflammation in mice

•IL-35 inhibits cigarette smoke-induced airway inflammation.•IL-35 reduces cigarette smoke-induced inflammatory cytokines production.•IL-35 increases anti-inflammatory cytokine IL-10 production in mice. Cigarette smoke (CS) is a very important cause of pulmonary inflammatory diseases. Interleukin (I...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomedicine & pharmacotherapy 2019-02, Vol.110, p.727-732
Hauptverfasser: Pan, Xiuhe, Xu, Keye, Li, Yuan, Wang, Xiaoying, Peng, Xiao, Li, Mingcai, Li, Yan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•IL-35 inhibits cigarette smoke-induced airway inflammation.•IL-35 reduces cigarette smoke-induced inflammatory cytokines production.•IL-35 increases anti-inflammatory cytokine IL-10 production in mice. Cigarette smoke (CS) is a very important cause of pulmonary inflammatory diseases. Interleukin (IL)-35 is a novel anti-inflammatory cytokine but its role in CS-mediated lung inflammation remains unclear. In the present study, we examined the effect of IL-35 expression on CS-induced lung inflammation in mice. A plasmid DNA expressing IL-35 was injected into mice via a hydrodynamic-based gene delivery that were subsequently exposed to CS three times a day for 5 days. We found that IL-35 expression inhibited pulmonary inflammatory infiltration, lung tissue lesions, mucus secretion, and myeloperoxidase activity in CS-treated mice. Moreover, IL-35 expression decreased the production of IL-1β, tumor necrosis factor-α, IL-6, and IL-17, but increased the level of IL-10 in bronchoalveolar lavage fluids and lung tissues from CS-challenged mice. These results suggest that in vivo expression of IL-35 can protect against CS-induced lung inflammation and may be a therapeutic target in CS-related pulmonary diseases.
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2018.12.028